Although small cell lung cancer (SCLC) responds dramatically to initial platinum-based chemotherapy, recurrences are nearly universal. The addition of atezolizumab, an immune checkpoint inhibitor, to front-line chemotherapy has recently demonstrated an improvement in overall survival (OS) in extensive stage SCLC (ES-SCLC). Subsequent lines of therapies are associated with modest efficacy in patients with relapsed disease, and the median overall survival is still 12 to 13 months at best.
Cirtuvivint is a small molecule inhibitor of the CDC2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs); inhibiting CLKs and DYRKs has been shown in preclinical models to cause tumor growth inhibition and sensitize cancer cells to cytotoxic chemotherapy.
This study is testing the hypothesis that adding cirtuvivint to chemotherapy in patients with relapsed SCLC will be well tolerated and improve the response rate and progression-free survival (PFS).

开始日期2025-12-18

申办/合作机构

Washington University School of Medicine

[+1]

NCT06856499

/ Recruiting临床1期IIT

Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer

The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy.
If a participant is a good fit for the study, and they enroll in the study, they will:
* Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days.
* Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.

开始日期2025-12-08

申办/合作机构

University of Colorado Denver

[+2]

NCT06484062

/ Recruiting临床1期IIT

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 is a combination of two drugs, decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Giving cirtuvivint alone or in combination with ASTX727 may be safe, tolerable, and/or effective in treating patients with AML and MDS.

开始日期2025-08-15

申办/合作机构

National Cancer Institute

100 项与 Cirtuvivint 相关的临床结果

登录后查看更多信息

100 项与 Cirtuvivint 相关的转化医学

登录后查看更多信息

100 项与 Cirtuvivint 相关的专利（医药）

登录后查看更多信息

项与 Cirtuvivint 相关的文献（医药）

2025-12-01·Cancer research communications

SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

Article

作者: Kusumoto, Shinya ; Nguyen, Lily L. ; Bitler, Benjamin G. ; Wick, Lars ; Jordan, Kimberly R. ; Corr, Bradley R. ; Bossard, Carine ; Barroilhet, Lisa ; Orsulic, Sandra ; Yamamoto, Tomomi M. ; Young, Alexandra ; Danhorn, Thomas ; Woodruff, Elizabeth R. ; Chuong, Edward B.

Abstract:

PARP inhibitors (PARPi) have reshaped the clinical management paradigm of multiple cancers, but none more than homologous recombination–deficient high-grade serous carcinoma (HGSC) of tubo-ovarian origin. In patients with HGSC that harbor BRCA1/2-mutations, PARPi maintenance therapy after first-line chemotherapy has resulted in significantly prolonged progression-free and overall survival. However, PARPi resistance is a major clinical challenge, and subsequent therapeutic options for patients with resistant disease remain limited. Whereas mechanisms of PARPi therapy have been described, there have been few clinical studies to translate these strategies into overcoming resistance. Elevated WNT signaling and T-cell factor (TCF) transcriptional activity contribute to PARPi resistance; however, directly targeting WNT signaling is challenging due to on-target adverse events. We tested an indirect WNT inhibitor, a dual CDC-like kinase and dual-specificity tyrosine phosphorylation–regulated kinase inhibitor, SM08502 (cirtuvivint), in combination with PARPi in multiple resistant HGSC models. We determined TCF transcriptional activity and differential gene expression with splicing analysis and used multispectral IHC to interrogate the tumor microenvironment. In PARPi-resistant models, SM08502 inhibits WNT/TCF transcriptional activity, reduces cell viability, and induces DNA damage. In addition, using multiple immune-compromised and immune-intact in vivo models of PARPi-resistant disease, SM08502, in combination with olaparib, significantly reduces disease progression, remodels the tumor immune microenvironment, and extends survival. Specifically, tumors treated with the SM08502/olaparib combination exhibit reduced immune-suppressive PD-1 and PD-L1 expression. This study provides strong preclinical evidence that SM08502, in combination with PARPi, may be an effective strategy to overcome PARPi resistance.

Significance::

PARPi resistance is a major clinical challenge. Overcoming PARPi resistance will provide patients with therapeutic options. The study shows, in the context of resistant disease, the potential of targeting CDC-like kinase/dual-specificity tyrosine phosphorylation–regulated kinase alone and in combination with PARP inhibitors.

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids

Article

作者: Coussens, Nathan P ; Silvers, Thomas ; Doroshow, James H ; Gore, Steven D ; Jones, Eric ; Teicher, Beverly A ; Dexheimer, Thomas S ; Kunkel, Mark

Abstract:

Purpose:

The alternative splicing of mRNA precursors allows one gene to yield multiple proteins with distinct functions. CDC-like kinases serve as pivotal regulators of alternative splicing. Control of protein expression also occurs at the level of DNA through histone methylation and demethylation. We investigated the activity of two CLK inhibitors, cirtuvivint and CC-671, and the LSD1 inhibitor iadademstat alone and in combination with anticancer drugs or investigational agents.

Methods:

Well-characterized patient-derived cancer cell lines from the PDMR (https://pdmr.cancer.gov/models/database.htm) were used along with standard human cancer cell lines. Multi-cell type-tumor spheroids were grown from a ratio of 6:2.5:1.5 malignant cells, endothelial cells, and mesenchymal stem cells. Following three days of growth, the spheroids were exposed to the single agents or combinations at concentrations up to the clinical Cmax value for each agent, if known. After seven days of exposure, cell viability was assessed using the CellTiter-Glo 3D assay and spheroid volume was assessed by bright field imaging.

Results:

Several of the targeted oncology drugs exhibited additive and greater-than-additive cytotoxicity when combined with a CLK inhibitor, or the LSD1 inhibitor. These agents included the XPO1 inhibitor, eltanexor, and the KRAS G12D specific inhibitor MRTX-1133 which had activity in tumor lines harboring the KRAS G12D mutation. LSD1 inhibition was effective with ubiquitin proteasome pathway inhibitors. Conclusion: These findings may provide guidance for development of clinical trial combination regimens including cirtuvivint, CC-671 or iadademstat. Full data sets are available on PubChem.

2025-02-01·Molecular Oncology

Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression

Article

作者: Anika Kremer ; Elisa Morales ; Frédéric R. Santer ; Florian Handle ; Glen Kristiansen ; Marcus V. Cronauer ; Jasper Van Goubergen ; Miroslav Peřina ; Oliver Schmidt

In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. Androgen receptor splice variant‐7 (ARV7) is clinically the most relevant and has a distinct 3′ untranslated region (3′UTR) compared to the AR full‐length variant, suggesting a unique post‐transcriptional regulation. Here, we set out to evaluate the applicability of the ARV7 3′UTR as a therapy target. A common single nucleotide polymorphism, rs5918762, was found to affect the splicing rate and thus the expression of ARV7 in cellular models and patient specimens. Serine/arginine‐rich splicing factor 9 (SRSF9) was found to bind to and increase the inclusion of the cryptic exon 3 of ARV7 during the splicing process in the alternative C allele of rs5918762. The dual specificity protein kinase CLK2 interferes with the activity of SRSF9 by regulating its expression. Inhibition of the Cdc2‐like kinase (CLK) family by the small molecules cirtuvivint or lorecivivint results in the decreased expression of ARV7. Both inhibitors show potent anti‐proliferative effects in enzalutamide‐treated or ‐naive PC models. Thus, targeting aberrant alternative splicing at the 3′UTR of ARV7 by disturbing the CLK2/SRSF9 axis might be a valuable therapeutic approach in late stage, ARSI‐resistant PC.

项与 Cirtuvivint 相关的新闻（医药）

2025-12-29

·今日头条

Cirtuvivint联合奥拉帕利启动1期临床，靶向卵巢癌耐药新通路

> 针对BRCA/HRD阳性且对铂类化疗耐药的复发性卵巢癌患者，一种旨在克服PARP抑制剂耐药的新型联合疗法已进入临床验证阶段。Biosplice Therapeutics公司近日宣布，其创新药物Cirtuvivint与已获批的PARP抑制剂奥拉帕利（Olaparib）的1期临床试验已完成首例患者给药。这标志着在应对这一治疗困境的攻坚战中，科学界正试图通过阻断癌细胞的DNA修复逃逸机制来打开新局面。 1. 临床试验启动：首例患者给药完成该试验是一项研究者发起的1期临床研究，专门针对**同源重组修复缺陷（HRD）阳性或携带BRCA基因突变，且对铂类药物耐药的复发性卵巢癌患者**。作为早期研究，其首要目标是评估**Cirtuvivint与奥拉帕利联合使用的安全性与耐受性**，并观察初步的抗肿瘤活性。 ![](blockview://markdown-image-tos-cn-i-tt/f5496eeee2c644948423da8d4ada559b) 首例患者的成功给药，意味着从临床前研究到人体试验的关键跨越已经实现。 2. 耐药困境：卵巢癌治疗的关键挑战卵巢癌的治疗长期面临高复发率的严峻挑战。约**70%的患者在初始治疗后的3年内会出现复发**。更为棘手的是，复发患者中相当一部分会对以顺铂为代表的铂类化疗产生耐药，即**铂耐药**，导致后续治疗选择有限，预后极差。即便对于已确立精准治疗地位的PARP抑制剂，耐药问题同样无法回避。这类药物通过 **“合成致死”** 机制发挥作用：在BRCA突变或HRD阳性导致DNA双链修复功能缺陷的肿瘤细胞中，抑制负责单链修复的PARP酶，可导致DNA损伤累积，最终引发细胞死亡。然而，肿瘤细胞会进化出新的修复通路（如微同源介导的末端连接）来绕过这一机制，从而导致PARP抑制剂失效。 3. 联合机制：靶向Polθ阻断逃逸通路 Cirtuvivint联合奥拉帕利的策略，核心在于对癌细胞DNA修复网络进行 **“双重封锁”** 。其科学依据在于： - **奥拉帕利** 继续抑制PARP介导的单链DNA修复。 - **Cirtuvivint** 作为一种**Polθ抑制剂**，旨在阻断肿瘤细胞在PARP被抑制后可能激活的备用修复通路。研究显示，**Polθ（由POLQ基因编码）在多种癌症中高表达，与预后不良及放化疗抵抗相关**。在BRCA缺陷的背景下，抑制Polθ可与PARP抑制产生协同效应，理论上能更彻底地瓦解癌细胞的DNA修复能力，逆转或防止耐药发生。这种策略被称为 **“合成致死的叠加”** 。 4. 借鉴先例：CAPRI试验证实联合策略潜力尽管Cirtuvivint是全新药物，但“联合DNA损伤反应抑制剂以克服PARP抑制剂耐药”的思路已有成功先例可循。一项名为 **CAPRI的II期临床试验** 为此提供了有力证据。 > 该研究针对13例对PARP抑制剂产生获得性耐药、但仍属铂敏感的同源重组缺陷卵巢癌患者，使用ATR抑制剂Ceralasertib联合奥拉帕利进行治疗。结果显示，联合疗法取得了显著的疗效： - **客观缓解率（ORR）达到50%**（6/12例患者达到部分缓解）。 - **中位无进展生存期（PFS）为7.43个月**。 - **86%的患者肿瘤标志物CA-125水平下降超过50%**，且多数患者在治疗3个周期内即出现最佳反应。该研究首次证实，在PARP抑制剂耐药人群中，联合其他靶向DNA损伤修复的药物仍能产生显著抗肿瘤活性，且安全性可控。这为Cirtuvivint的研发路径提供了重要的临床逻辑支撑。 5. 未来展望：新靶点与治疗趋势此次1期临床试验的启动，是卵巢癌治疗向更精细化的联合靶向策略迈进的一个缩影。随着对耐药机制理解的深入，针对**Polθ、ATR、WEE1**等新靶点的药物研发日益活跃。此外，临床实践也在探索不同联合模式的边界。例如，**PAOLA-1研究的最终数据显示，奥拉帕利联合贝伐珠单抗用于HRD阳性患者一线维持治疗，中位总生存期（OS）达到75.2个月**，展现了联合治疗的长期获益潜力。同时，**FZOCUS-1等研究则提示，在部分患者群体中，PARP抑制剂单药与联合抗血管药物的疗效可能相当**，强调了基于生物标志物的精准分层重要性。对于**铂耐药且PARP抑制剂耐药的卵巢癌患者**而言，Cirtuvivint联合奥拉帕利的探索尽管处于早期阶段，但其代表了一种从机制源头应对耐药的努力方向。未来，该试验的安全性及初步疗效数据，将决定这一新联合方案能否为困境中的患者带来实质性的治疗转机。

临床1期临床2期临床结果

2025-12-29

·癌度

《癌度快报》2025年12月29日：明星抗癌药RMC-6236启动三期临床试验，用于术后辅助治疗预防复发！

临床试验病友交流群（点击）一、新药快讯 1、明星抗癌药RMC-6236启动三期临床试验，用于术后辅助治疗预防复发！近日，针对RAS基因的靶向药Daraxonrasib（RMC-6236）针对可切除胰腺导管腺癌的III期临床试验RASolute304完成首例患者入组。该研究计划纳入500例携带RAS突变、已完成手术及围手术期化疗的患者，评估RMC-6236相较于观察组在无病生存期（DFS）方面的改善效果。该口服药物可靶向抑制包括G12X、G13X、Q61X在内的多种RAS致癌突变，直接阻断RAS信号通路。胰腺癌中超过90%存在RAS突变，此前缺乏有效靶向疗法，该试验若成功，则有望为术后患者提供重要防复发手段。目前RMC-6236共开展4项全球III期研究，涵盖胰腺癌与非小细胞肺癌。 2、又一款国产PD-L1和VEGF双抗HB0025拟启动三期临床，治疗晚期肺癌！ 2025年12月29日，我国自主研发的PD-L1和VEGF双特异性融合蛋白HB0025注射液获CDE拟启动III期临床试验，拟用于一线治疗鳞状及非鳞状非小细胞肺癌。该药通过同步阻断免疫检查点PD-L1与血管生成通路VEGF，实现“免疫激活+抗血管”双机制协同。II期研究（ESMO 2025）显示其在肺鳞癌/肺腺癌中客观缓解率与疾病控制率良好，PD-L1阴性人群响应显著，3级以上免疫相关不良事件发生率低。目前全球同靶点双抗中，依沃西单抗已上市，还有几款药物处于III期阶段，欢迎大家联系癌度申请临床试验免费使用。 3、卵巢癌耐药后怎么办？SM08502联合奥拉帕利组合开始为首位患者治疗用药！近日，CLK/DYRK激酶抑制剂Cirtuvivint (代号SM08502) 联合PARP抑制剂奥拉帕利的I期临床试验完成首例患者给药，用于治疗BRCA突变/HRD阳性铂类耐药卵巢癌。该研究由科罗拉多大学医院主导，采用剂量递增设计，旨在评估联合用药安全性及确定II期推荐剂量。临床前研究显示，SM08502可通过抑制WNT/β-连环蛋白信号通路逆转PARP抑制剂耐药，在卵巢癌模型中与奥拉帕利协同诱导DNA损伤、延缓肿瘤进展。该联合方案有望为PARP抑制剂耐药患者提供新治疗策略。二、抗癌前沿 1、如何发现早期结直肠癌，有幸存者亲自讲述了4种早期的相关症状！结直肠癌的早期预警，主要是有便血、排便习惯改变、不明原因体重下降、持续疲劳为四大核心症状。美国MD安德森癌症中心专家指出，若上述症状持续超2周就需立即就医。通过对6位幸存者的案例分析显示：37岁患者持续数月便血误认为工作繁忙延误诊断；19岁患者将排便不规律归因饮食改变，确诊时已为IV期；66岁感染病专家忽视4个月持续消瘦，经家人提醒后确诊I期。专家指出直肠出血、黑便、缺铁性贫血属高危警示信号，应及时做检查以排除是否为结直肠癌。 “吉爱3000”惠民检项目，最低2000+可及的基因检测专属福利，全球新药临床试验免费用药、基因检测报告解读，详情微信“长按”下图扫码联系癌度王博进行咨询。另外，由于微信公众平台的机制调整，恳请各位粉丝朋友花一两秒钟帮我们点亮文章下方的【小手】和【爱心】，这对我们至关重要。谢谢大家！点亮小手爱心，送来温暖鼓励

临床2期临床3期临床1期

2025-12-28

·药明康德

针对绝大多数结直肠癌，创新T细胞衔接器获美国FDA快速通道资格；小分子组合疗法旨在克服PARP抑制剂耐药…… | 一周盘点

本期看点： 1. 靶向新型肿瘤抗原LY6G6D的T细胞衔接器CBI-1214的IND申请已获得美国FDA批准，并被授予快速通道资格。 2. 选择性泛CLK/泛DYRK激酶抑制剂cirtuvivint与PARP抑制剂olaparib联用治疗携带BRCA突变和/或同源重组缺陷（HRD）的铂类耐药卵巢癌女性患者，该1期联合治疗试验已完成首例患者给药。 CBI-1214：IND申请获得FDA许可 Cartography Biosciences公司宣布，其候选药物CBI-1214的IND申请已获得美国FDA批准，并被授予快速通道资格。公司计划在2026年第一季度启动CBI-1214用于治疗结直肠癌（CRC）的1期临床试验。 CBI-1214是一种T细胞衔接器，靶向一种名为LY6G6D的新型肿瘤抗原。该抗原在健康组织中几乎不表达，却特异性地存在于微卫星稳定型（MSS）和微卫星不稳定性低（MSI-L）的结直肠癌亚型中——这两类患者占CRC患者的绝大多数，且具有巨大的未竟医疗需求。CBI-1214通过蛋白工程优化，旨在增强其抗肿瘤活性，有望成为高度特异性的肿瘤抗原疗法。 Cirtuvivint：1期联合治疗试验完成首例患者给药 Biosplice Therapeutics公司宣布，其开展的一项1期临床试验已为首位患者给药，该试验旨在评估小分子药物cirtuvivint与PARP抑制剂olaparib联用治疗携带BRCA突变和/或HRD的铂类耐药卵巢癌女性患者。该研究尤其针对既往已接受过PARP抑制剂治疗的患者。Cirtuvivint是一种选择性泛CLK/泛DYRK激酶抑制剂，通过调控RNA选择性剪接（包括参与致癌通路的转录本）发挥抗肿瘤作用。临床前研究表明，cirtuvivint可通过抑制CLK/DYRK激酶，间接阻断肿瘤细胞在PARP抑制剂压力下激活的“备用生存通路”——WNT/TCF信号通路。在多种BRCA突变或HRD的高级别浆液性卵巢癌耐药模型中，cirtuvivint不仅抑制WNT/TCF转录活性、降低核内β-catenin水平，还诱导DNA损伤、降低肿瘤细胞存活能力，并与olaparib协同延缓肿瘤进展、延长生存期（无论在免疫正常或免疫功能低下的动物模型中均有效）。此外，该药还能改善肿瘤免疫微环境，例如减少免疫抑制性PD-1/PD-L1表达细胞。这些数据为临床探索cirtuvivint联合olaparib以克服或延缓PARP抑制剂耐药提供了有力依据。 IMP761：公布1期临床试验数据 Immutep公司宣布，其在健康受试者中开展的首个人体、安慰剂对照、双盲1期临床试验取得积极进展，该试验旨在评估IMP761——一种潜在“first-in-class”的LAG-3激动型抗体，用于治疗自身免疫性疾病。IMP761通过特异性沉默聚集在病灶部位的自身免疫记忆T细胞，有望从根源上干预多种自身免疫疾病，并恢复免疫系统平衡。该研究的单次递增剂量部分已顺利完成2.5 mg/kg和7 mg/kg两个剂量组的给药。IMP761展现出良好的安全性，未出现超出轻度的治疗相关不良反应。同时，观察到IMP761具有明确的剂量依赖性免疫抑制效应，在第2天、第9天和第23天，IMP761显著且持久地抑制了受试者对强异源抗原引发的三种T细胞介导的皮内反应。T细胞活性的显著降低凸显了IMP761在治疗自身免疫疾病中的潜在疗效。参考资料： [1] Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer. Retrieved December 26, 2025, from https://www.businesswire.com/news/home/20251218346181/en/Cartography-Receives-FDA-Investigational-New-Drug-IND-Approval-and-Fast-Track-Designation-for-Lead-Program-CBI-1214-for-Colorectal-Cancer [2] Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV). Retrieved December 26, 2025, from https://www.globenewswire.com/news-release/2025/12/18/3207665/0/en/Ovid-Therapeutics-Reports-Phase-1-Results-for-the-First-Ever-Direct-Activator-of-Potassium-Chloride-Cotransporter-2-KCC2-OV350-Intravenous-IV.html [3] 에이비엘, 'ROR1xB7-H3 ADC' 1상 “FDA IND 제출”. Retrieved December 26, 2025, from https://www.biospectator.com/news/view/27335 [4] Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer. Retrieved December 26, 2025, from https://www.globenewswire.com/news-release/2025/12/22/3209045/0/en/Biosplice-Therapeutics-Announces-First-Patient-Dosed-in-Investigator-Initiated-Phase-1-Clinical-Trial-of-Cirtuvivint-and-Olaparib-in-BRCA-HRD-Platinum-Resistant-Ovarian-Cancer.html [5] Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy. Retrieved December 26, 2025, from https://www.globenewswire.com/news-release/2025/12/22/3209226/0/en/Imviva-Biotech-Announces-First-Patient-Dosed-in-Phase-1b-2-TENACITY-01-Trial-of-CTD402-CAR-T-Cell-Therapy.html [6] Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study. Retrieved December 26, 2025, from https://www.globenewswire.com/news-release/2025/12/22/3209162/0/en/Immutep-Announces-Positive-Update-on-IMP761-a-First-in-Class-LAG-3-Agonist-Antibody-for-Autoimmune-Diseases-from-Phase-I-Study.html [7] Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer. Retrieved December 26, 2025, from https://www.prnewswire.com/news-releases/curasight-announces-successful-dosing-of-first-patient-in-phase-1-trial-with-utreat-in-brain-cancer-302646271.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床1期快速通道临床申请临床结果临床2期

100 项与 Cirtuvivint 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
小细胞肺癌	临床2期	美国	Biosplice Therapeutics, Inc.	2025-12-18
软组织肉瘤	临床2期	西班牙	Biosplice Therapeutics, Inc.	2025-05-01
乳腺癌	临床1期	美国	University of Colorado Denver	2025-12-08
卵巢子宫内膜样癌	临床1期	美国	University of Colorado Denver	2025-12-08
输卵管癌	临床1期	美国	University of Colorado Denver	2025-12-08
铂耐药性卵巢癌	临床1期	美国	University of Colorado Denver	2025-12-08
铂类耐药性原发性腹膜癌	临床1期	美国	University of Colorado Denver	2025-12-08
伴有骨髓发育不良相关变化的急性髓系白血病	临床1期	美国	National Cancer Institute	2025-08-15
复发性骨髓增生异常综合征	临床1期	美国	National Cancer Institute	2025-08-15
难治性急性髓细胞白血病	临床1期	美国	National Cancer Institute	2025-08-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CTIS2024-511987-10-00 (SELNET-7-2, ESMO2025)	临床2期	软组织肉瘤二线	25	Cirtuvivint 80 mg	繭鹹夢選齋網憲餘鹽糧(構繭網願鹽構鹹簾簾蓋) = 獵範襯鏇醖齋網鹽簾膚觸艱艱鑰鏇顧襯憲夢觸 (鹽蓋顧衊壓觸艱遞鹽窪, 50.9 ~ 84.4) 更多	积极	2025-10-17
NCT05084859 \| NCT03355066 (ESMO2022) 人工标引	临床1期	晚期恶性实体瘤 \| 非小细胞肺癌 \| 结直肠癌 ... ARV7 Positive 更多	65	cirtuvivint+abiraterone acetate+FOLFIRI-panitumumab/docetaxel	膚遞蓋鏇餘憲築範襯餘(蓋襯廠積窪蓋繭選壓壓) = 襯鏇鹹壓醖蓋構選簾壓願積鬱餘築觸糧餘築選 (鬱膚構顧鬱廠糧淵簾衊 ) 更多	积极	2022-09-10
NCT03355066 (FIH（Biosplice）, AACR 12021 \| AACR 22021) 人工标引	临床1期	晚期恶性实体瘤	19	SM08502	鑰襯餘鬱壓膚選餘醖繭(蓋淵顧簾願衊遞齋壓願) = diarrhea (2/19 [10.5%]) 廠鬱淵顧淵構窪積鬱範 (窪顧鏇夢糧艱鹹繭餘製 ) 更多	积极	2021-07-01
NCT03355066 (AACR2020)	临床1期	HR阳性乳腺癌	82	SM08502	醖壓範膚膚壓繭範憲膚(蓋齋鹽蓋餘願糧獵襯鏇) = 衊鹹鏇膚製鬱觸範鬱蓋簾壓糧網艱獵衊壓簾醖 (衊簾夢築鏇鏇顧簾製壓, <0.001)	-	2020-08-15
NCT03355066 (AACR2020)	临床1期	HR阳性乳腺癌	82	Fulvestrant	醖壓範膚膚壓繭範憲膚(蓋齋鹽蓋餘願糧獵襯鏇) = 選觸鬱網廠築願艱範觸簾壓糧網艱獵衊壓簾醖 (衊簾夢築鏇鏇顧簾製壓, 0.34)	-	2020-08-15
NCT03355066 (AACR2020)	临床1期	去势抵抗性前列腺癌	82	SM08502	鑰築齋鏇廠網襯衊繭膚(顧憲觸網製網齋製壓積) = 鹽蓋築糧願醖廠選齋範鑰遞蓋艱鹽蓋鬱積膚餘 (衊繭獵襯憲艱襯壓積觸 ) 更多	-	2020-08-15
NCT03355066 (AACR2020)	临床1期	去势抵抗性前列腺癌	82	Abiraterone	鑰築齋鏇廠網襯衊繭膚(顧憲觸網製網齋製壓積) = 鑰範淵窪醖繭襯願窪繭鑰遞蓋艱鹽蓋鬱積膚餘 (衊繭獵襯憲艱襯壓積觸 )	-	2020-08-15
NCT03355066 (P3-13-01, SABCS2020)	临床1期	三阴性乳腺癌	-	SM08502	積觸製鬱窪觸構構願觸(鑰廠範遞憲夢範壓餘鏇) = 壓積網製鬱製窪願範鏇壓夢觸夢淵夢鹽衊顧鬱 (膚網願積膚艱構願憲鹽, 0.055 ~ 0.510) 更多	-	2020-02-15
NCT03355066 (P3-13-01, SABCS2020)	临床1期	三阴性乳腺癌	-	Gemcitabine (G)/Nab-paclitaxel (Nab-P)	簾獵網築蓋鏇願壓廠範(範憲積願顧願鹽鹽願遞) = 鹹鏇鬱餘襯窪蓋鹽顧鬱衊齋觸構積顧鹽繭範顧 (鬱廠襯鏇鏇積築鑰鏇憲 )	-	2020-02-15
NCT03355066 (ASCO2019)	临床1期	结直肠癌	82	SM08502	遞觸齋網願鏇築範積廠(壓構鏇糧範製膚壓齋醖) = 鏇齋選淵獵艱積糧築窪鹽襯簾齋願蓋齋襯艱製 (蓋鹹餘繭襯餘鹹築憲鑰 ) 更多	-	2019-05-26